-
It is now focused on seeking treatments for major eye diseases, including Wet AMD, or age-related macular degeneration.
FORBES: Teva Chairman Continues To Seek Undervalued Biopharmaceuticals
-
The proteins were activated in mice bred to mimic the effects of age-related macular degeneration (AMD) and diabetic retinopathy.
BBC: NEWS | Health | Protein 'reverses eye diseases'
-
That could represent further problems for Eyetech, which, along with Pfizer, already sells a treatment called Macugen for the disease--age-related macular degeneration (AMD).
FORBES: Magazine Article
-
Eyetech shares soared last year based on the success of Macugen, a treatment for age-related macular degeneration (AMD), a leading cause of blindness.
FORBES: OSI Chief Explains $935 Million Eyetech Buy
-
By the end of the study, the researchers showed that 9.3% of patients taking aspirin developed wet age-related macular degeneration (AMD) compared with 3.7% of patients who did not take aspirin.
BBC: Long-term aspirin 'blindness link'
-
Studies from two different teams published Monday in the Archives of Ophthalmology provide more evidence that these foods -- which contain healthy fats -- can reduce the risk of developing a retina-destroying condition known as age-related macular degeneration (AMD).
CNN: Fish, olive oil, nuts good for eyes too, more studies find
-
That could represent further problems for Eyetech (nasdaq: EYET - news - people ), which, along with Pfizer (nyse: PFE - news - people ), already sells a treatment called Macugen for the disease--age-related macular degeneration (AMD).
FORBES: More Eye-Opening Data From Genentech
-
There are two forms of age-related macular degeneration, or AMD: the dry form, known as non-neovascular, and the wet form, called neovascular.
CNN: New techniques slow progress of age-related vision loss
-
Two breakthrough drugs from Genentech offer hope for patients with the more severe "wet" form (which is more common in Asia than in the U.S.) of age-related macular degeneration, or AMD.
FORBES: Magazine Article
-
Two breakthrough drugs from Genentech (nyse: DNA - news - people ) offer hope for patients with the more severe "wet" form of age-related macular degeneration, or AMD.
FORBES: Banishing Blind Spots
-
Two breakthrough drugs from Genentech (nyse: DNA - news - people ) offer hope for patients with the more severe "wet" form (which is more common in Asia than in the U.S.) of age-related macular degeneration, or AMD.
FORBES: Banishing Blind Spots